U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

详细摘要
First at-home treatment provides a new option for patients and caregivers to address agitation outside of a healthcare settingApproval is supported by results of the Phase 3 SERENITY Trial, in
PARSIPPANY, N.J., Nov. 16, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the U.S. Food and Drug Administration (FDA) approval of IGALMI (dexmedetomidine) sublingual film for at-home use. With this approval, IGALMI becomes the first FDA-approved treatment that can be used at home for agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.
“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” said Chris Fox, Executive Vice President, U.S. Commercial and Head of Innovative Franchise at Teva. “With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it, reflecting Teva’s commitment to improving how care is experienced in everyday life.”
Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder affects between 25% and 40% of patients across these conditions.2 Acute agitation can escalate quickly, creating significant challenges for patients, families and caregivers and, in up to 21% of cases, can result in an emergency department visit or hospitalization.3
“Innovation in neuroscience is about discovering new medicines and also about rethinking when, where and how treatment can be delivered,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva. “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”
In the Phase 3 SERENITY At-Home Safety and Tolerability Trial, 1,160 agitation episodes in 102 patients were treated with IGALMI, and tolerability remained consistent with repeat dosing over the 12-week…
Tev…
文章开头,摘自Toronto Star。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.thestar.com)



/https://i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2026/b/V/p2J2BOSiy0VBzYjLjK1g/img-9783.jpg.jpeg)
